The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations
- PMID: 19184328
- DOI: 10.1007/s10238-008-0026-9
The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations
Abstract
Repeated administration of L-asparaginase leads to the development of specific antibodies and hypersensitivity reactions. The aim of the study was to evaluate a possible cross-reaction of anti-asparaginase antibodies, developed against the native E. coli L-asparaginase (Asparaginase Medac), with other preparations of the enzyme. Sixteen patients with acute lymphoblastic leukemia, in whom in the reinduction phase of treatment hypersensitivity against L-asparaginase was observed and/or the presence of anti-asparaginase antibodies was established were recruited for the present study. Ten out of 16 tested sera showed cross-immunoreactivity to PEG-asparaginase, while no reactivity to L-asparaginase derived from Erwinia chrysantemi was observed. Since cross-reacting antibodies were also found in sera of patients with no overt allergic reaction, L: -asparaginase may undergo silent inactivation during the reinduction phase of therapy. This finding is of clinical importance with regard to appropriate dosage and necessitates careful enzyme activity monitoring in all patients undergoing repeated treatment with various L-asparaginase preparations.
Similar articles
-
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.Leukemia. 2003 Aug;17(8):1583-8. doi: 10.1038/sj.leu.2403011. Leukemia. 2003. PMID: 12886246
-
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.J Immunol Methods. 2000 May 26;239(1-2):75-83. doi: 10.1016/s0022-1759(00)00182-4. J Immunol Methods. 2000. PMID: 10821949
-
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.Leukemia. 1998 Oct;12(10):1527-33. doi: 10.1038/sj.leu.2401162. Leukemia. 1998. PMID: 9766495
-
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?Pediatr Blood Cancer. 2021 Oct;68(10):e29169. doi: 10.1002/pbc.29169. Epub 2021 Jun 8. Pediatr Blood Cancer. 2021. PMID: 34105243 Review.
-
A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.Biotechnol Appl Biochem. 2020 Jul;67(4):619-647. doi: 10.1002/bab.1888. Epub 2020 Feb 18. Biotechnol Appl Biochem. 2020. PMID: 31954377 Review.
Cited by
-
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.Leuk Res. 2016 Nov;50:17-20. doi: 10.1016/j.leukres.2016.08.014. Epub 2016 Aug 26. Leuk Res. 2016. PMID: 27631159 Free PMC article.
-
Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia.Front Oncol. 2023 Feb 1;13:1070069. doi: 10.3389/fonc.2023.1070069. eCollection 2023. Front Oncol. 2023. PMID: 36816964 Free PMC article. Review.
-
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.Invest New Drugs. 2022 Feb;40(1):21-29. doi: 10.1007/s10637-021-01173-8. Epub 2021 Sep 1. Invest New Drugs. 2022. PMID: 34468906 Free PMC article.
-
Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.Pathol Oncol Res. 2015 Sep;21(4):909-20. doi: 10.1007/s12253-015-9912-0. Epub 2015 Mar 6. Pathol Oncol Res. 2015. PMID: 25740072
-
Allergic reactions to asparaginase: retrospective cohort study in pediatric patients with acute lymphoid leukemia.Hematol Transfus Cell Ther. 2021 Jan-Mar;43(1):9-14. doi: 10.1016/j.htct.2019.10.007. Epub 2020 Jan 22. Hematol Transfus Cell Ther. 2021. PMID: 32014473 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources